Trial Profile
Silent cerebral microvascular disease and longitudinal risK of cognitive decline in Atrial Fibrillation study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Oct 2017
Price :
$35
*
At a glance
- Drugs Edoxaban (Primary)
- Indications Embolism and thrombosis
- Focus Pharmacodynamics
- Acronyms SKAF Study
- Sponsors Daiichi Sankyo Company
- 04 Oct 2017 New trial record
- 02 Oct 2017 Planned initiation date changed from 1 Oct 2017 to 1 Nov 2017.